期刊文献+

辛伐他汀治疗69岁以上老年高脂血症患者的安全性及临床疗效──附78例报告 被引量:3

下载PDF
导出
摘要 目的:探讨辛伐他汀用于69岁以上高脂血症患者的调脂疗效、安全性及预防心血管事件的作用。方法:将153例69岁以上的老年高脂血症患者随机单盲分为两组:辛伐他汀组78例,辛伐他汀20mg/d;安慰剂组75例,安慰剂1粒/日,疗程均为1年。观察调脂效果、心脏性事件及不良反应发生情况。结果:辛伐他汀组治疗后总胆固醇、甘油三酯、LDL-C、载脂蛋白(Apo)B均明显下降(P<0.001),HDL-C、ApoA1均显著升高(P<0.01),上述各项与对照组比较,均为P<0.001;辛伐他汀组调脂总达标率、总胆固醇达标率、LDL-C达标率、甘油三酯达标率分别为76%、81%、79%、62%。随访1年显示:辛伐他汀组不稳定型心绞痛(NSAP)、非致命性心肌梗死、心力衰竭发生危险性均较安慰剂组明显下降(均为P<0.05);各种心律失常、需做经皮腔内冠状动脉造影术(PTCA)/冠状动脉旁路移植术(CABG)、脑卒中、心脏性病死率及总病死率均有下降,但P>0.05;辛伐他汀组不良反应轻微,为7%,与安慰剂组的5%相似,但随年龄的增高,不良反应发生率有增加的倾向。结论:应用辛伐他汀20mg/d治疗69岁以上高脂血症患者能全面调脂,预防心脏性事件发生,不良反应轻微。
出处 《新医学》 北大核心 2002年第4期209-210,共2页 Journal of New Medicine
  • 相关文献

参考文献4

二级参考文献15

  • 1曾群英 张育君.辛伐他汀(舒降之)治疗冠心病高胆固醇血症的临床研究[J].新医学,1998,29(1):11-13.
  • 2[1]Carlson LA, Rosenhamer G. Reduction in mortlity in Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand, 1988;223:405~418
  • 3[2]Buchwald H, Matts JP, Fitch LL, et al. for the Program on the Surgical Control of Hyperlipidemias (POSCH)Group: Changes in sequential coranary arteriograms and subsequent coronary events. JAMA,1992;268:1429
  • 4[3]Scandinavian Simvastatin Survival Study(4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.Lancet, 1994; 344:1383~ 1389
  • 5[4]Sacks FM, Pfeffer MA, Moye LA,et al. for the Cholesterol And Recurrent Events Trial(CARE). The effect of pravastatin on coronaryevents after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996; 335:1001~1009
  • 6[5]National Cholesterol Education Program: Second report of the expert on detection, evaluation, and treatment of high blood cholesterol in adult. Circulation, 1994;89:1329
  • 7[6]The Long Term Investigation With Pravastatin In Ischaemic Disease (LIPID)Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339:1349~1357
  • 8[7]Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary disease in men with hypercholesterolemia. West of Scotland Coronary Prevention Study (WOSCOPS) Group. N Engl J Med, 1995; 333:1301~1307
  • 9[8]Down JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA,1998;279:1615~1622
  • 10曾群英,新医学,1998年,29卷,增1期,11页

共引文献4471

同被引文献29

引证文献3

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部